TCTC Holdings LLC Acquires 251 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

TCTC Holdings LLC boosted its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 10.0% during the 4th quarter, Holdings Channel reports. The firm owned 2,764 shares of the biopharmaceutical company’s stock after buying an additional 251 shares during the period. TCTC Holdings LLC’s holdings in Gilead Sciences were worth $255,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the business. HHM Wealth Advisors LLC increased its stake in Gilead Sciences by 118.5% in the 4th quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 154 shares during the last quarter. YANKCOM Partnership bought a new stake in Gilead Sciences in the 4th quarter worth approximately $28,000. Decker Retirement Planning Inc. bought a new stake in Gilead Sciences in the 4th quarter worth approximately $29,000. Crews Bank & Trust bought a new stake in Gilead Sciences in the 4th quarter worth approximately $31,000. Finally, Stephens Consulting LLC increased its stake in Gilead Sciences by 325.0% in the 4th quarter. Stephens Consulting LLC now owns 340 shares of the biopharmaceutical company’s stock worth $31,000 after acquiring an additional 260 shares during the last quarter. Institutional investors own 83.67% of the company’s stock.

Analyst Ratings Changes

GILD has been the topic of a number of research reports. Bank of America lifted their price objective on Gilead Sciences from $116.00 to $126.00 and gave the stock a “buy” rating in a research note on Wednesday, March 5th. Needham & Company LLC reiterated a “hold” rating on shares of Gilead Sciences in a report on Wednesday, February 12th. Deutsche Bank Aktiengesellschaft upgraded Gilead Sciences from a “hold” rating to a “buy” rating and lifted their target price for the stock from $80.00 to $120.00 in a report on Tuesday, February 18th. Piper Sandler lifted their target price on Gilead Sciences from $105.00 to $110.00 and gave the stock an “overweight” rating in a report on Wednesday, February 12th. Finally, The Goldman Sachs Group lifted their target price on Gilead Sciences from $85.00 to $96.00 and gave the stock a “neutral” rating in a report on Wednesday, February 12th. Eleven research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and four have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $104.52.

Gilead Sciences Trading Down 1.7 %

Shares of NASDAQ GILD opened at $111.44 on Monday. The company has a quick ratio of 1.20, a current ratio of 1.50 and a debt-to-equity ratio of 1.24. The business has a fifty day simple moving average of $101.82 and a two-hundred day simple moving average of $92.92. The firm has a market cap of $138.78 billion, a PE ratio of 301.19, a price-to-earnings-growth ratio of 0.71 and a beta of 0.21. Gilead Sciences, Inc. has a twelve month low of $62.07 and a twelve month high of $119.96.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share for the quarter, beating analysts’ consensus estimates of $1.67 by $0.23. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. Analysts expect that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, March 28th. Stockholders of record on Friday, March 14th will be given a $0.79 dividend. This represents a $3.16 annualized dividend and a dividend yield of 2.84%. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.77. The ex-dividend date is Friday, March 14th. Gilead Sciences’s payout ratio is presently 854.05%.

Insider Transactions at Gilead Sciences

In other news, CFO Andrew D. Dickinson sold 17,929 shares of the business’s stock in a transaction on Monday, March 10th. The stock was sold at an average price of $118.17, for a total value of $2,118,669.93. Following the completion of the transaction, the chief financial officer now directly owns 169,061 shares of the company’s stock, valued at approximately $19,977,938.37. The trade was a 9.59 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In the last three months, insiders sold 302,785 shares of company stock valued at $30,503,250. Corporate insiders own 0.16% of the company’s stock.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.